Tag: biotech stocks
-
Medexus Pharmaceuticals (MDP.TO): A growing core business breaking company records
*originally published 01-16-23 Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs that are already licensed in Western Europe and then bringing them to North America. A very smart business model which has seen Medexus carve…
-
Perimeter Medical Imaging AI (PINK.V): They’re not curing cancer here, but they’ll help dig it out..
For the last eight months, the Covid-19 virus has been the center of attention in the media, the markets, and the medical field. Collectively, countries and government agencies, and academia, and pharmaceutical companies, have poured hundreds of millions into efforts combating the plague that has left so many countries and populations struggling, but despite the…
-
Market Meltdown: gold & housing: “It’s not the pins – it’s the bubble”.
“It’s the financials that are really getting killed,” stated Schiff, “They have made all the loans that are not going to get repaid, so this is just like 2008, only it’s not just the banks that are going to need a bailout, it’s the hotels, it’s the airlines, it’s companies like Boeing, it’s the cruise…
-
DJIA plummets: divorce lawyers shudder as poor sexless couples grope each other in the night
“The National Marriage Project dubbed the drop in divorce ‘a silver lining’ to the Great Recession,” stated The L.A. Times, “arguing that tough times were pulling many husbands and wives closer together.”
-
Did Aytu BioScience (AYTU.Q) just SpankChain the NASDAQ?
When a sector gets hot, small cap stocks can often get a bump by sidling up to the hot sector with a new product/idea/opportunity. When the dust clears, the intrinsic value of the new offering is typically deemed to be low. We saw it in 3D-printing, with Dung Beetle Treats. We saw it in weed…
-
Moderna’s (MRNA.Q) “Coronavirus Vaccine” announcement – causes $3.4 billion jump in market cap
We’ll take a wild guess that precisely NONE of the retail investors who just drove up the price of the MRNA would recognise a “stabilized form of S protein” if they met it on a beach, made sand castles with it – then took it home to play Spin-The-Bottle.